Latest Articles

Publication Date
Surgical Reconstruction of Abdominal Wall Endometriosis Post-Cesarean Section: A Monocentric Experience of a Rare Pathology.

Background: Abdominal wall endometriosis (AWE) is a rare pathological condition that mostly occurs in the post-cesarean section. This study aimed to describe the surgical approach employed in treating 31 patients …

Published: Aug. 1, 2025, midnight
Main Differential Endometrial Microbiota Associated With Recurrent Implantation Failure: A case control study - Frontiers

Main Differential Endometrial Microbiota Associated With Recurrent Implantation Failure: A case control study Frontiers

Published: July 23, 2025, 7:48 p.m.
Molecular subtype of recurrent implantation failure reveals distinct endometrial etiology of female infertility - Journal of Translational Medicine

Molecular subtype of recurrent implantation failure reveals distinct endometrial etiology of female infertility Journal of Translational Medicine

Published: July 14, 2025, 11:45 a.m.
BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer - TipRanks

BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer TipRanks

Published: July 11, 2025, 4:24 p.m.
Dr Pothuri on Current Unmet Needs in Recurrent/Advanced Endometrial Cancer - OncLive

Dr Pothuri on Current Unmet Needs in Recurrent/Advanced Endometrial Cancer OncLive

Published: July 1, 2025, 4:14 p.m.
The role of m6A methylation in female reproductive physiology and pathology.

N6-methyladenosine (m6A) is a critical regulator of female reproductive physiology, yet existing reviews have focused predominantly on oocytes. The objective of this review is to systematically evaluate the regulatory effects …

Published: July 1, 2025, midnight
Selinexor Maintenance Displays Durable Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer - OncLive

Selinexor Maintenance Displays Durable Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer OncLive

Published: June 25, 2025, 9:58 p.m.
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - Physician's Weekly

Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer Physician's Weekly

Published: June 10, 2025, 6:31 a.m.
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - HealthDay

Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer HealthDay

Published: June 9, 2025, 2:50 p.m.
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer BioSpace

Published: June 9, 2025, 12:43 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!